Adial Historical Financial Ratios
| ADIL Stock | USD 1.09 0.01 0.91% |
Adial Pharmaceuticals is presently reporting on over 92 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.68 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Adial Pharmaceuticals financial condition quickly.
Adial |
About Adial Financial Ratios Analysis
Adial PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Adial Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Adial financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Adial Pharmaceuticals history.
Adial Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Adial Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Adial Pharmaceuticals sales, a figure that is much harder to manipulate than other Adial Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Adial Pharmaceuticals dividend as a percentage of Adial Pharmaceuticals stock price. Adial Pharmaceuticals dividend yield is a measure of Adial Pharmaceuticals stock productivity, which can be interpreted as interest rate earned on an Adial Pharmaceuticals investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Adial Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Adial Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.At this time, Adial Pharmaceuticals' EV To Operating Cash Flow is quite stable compared to the past year. Net Debt To EBITDA is expected to rise to 0.42 this year, although the value of Operating Cash Flow Per Share will most likely fall to (5.02).
Adial Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Adial Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adial Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 3.33 | 5.32 | 14.31 | 1.78 | 0.65 | 0.68 | |
| Book Value Per Share | 18.12 | 8.0 | 4.72 | 3.08 | 2.87 | 4.97 | |
| Free Cash Flow Yield | (0.27) | (0.36) | (0.24) | (1.91) | (2.2) | (2.09) | |
| Operating Cash Flow Per Share | (16.08) | (15.31) | (16.07) | (10.52) | (4.78) | (5.02) | |
| Average Payables | 144.9K | 419.5K | 467.5K | 201.9K | 181.7K | 232.7K | |
| Pb Ratio | 3.33 | 5.32 | 14.31 | 1.78 | 0.65 | 0.68 | |
| Free Cash Flow Per Share | (16.08) | (15.31) | (16.16) | (10.52) | (12.1) | (12.71) | |
| Roic | (1.14) | (2.73) | (5.47) | (3.99) | (1.69) | (1.77) | |
| Net Income Per Share | (21.8) | (21.79) | (26.12) | (11.98) | (4.92) | (5.16) | |
| Payables Turnover | 0.00297 | 8.69E-4 | 0.19 | 0.22 | 0.004427 | 0.004206 | |
| Cash Per Share | 17.2 | 8.83 | 8.15 | 3.76 | 1.99 | 1.89 | |
| Pocfratio | (3.75) | (2.78) | (4.2) | (0.52) | (0.39) | (0.41) | |
| Pfcf Ratio | (3.75) | (2.78) | (4.18) | (0.52) | (0.47) | (0.49) | |
| Days Payables Outstanding | 122.9K | 419.8K | 1.9K | 1.7K | 82.4K | 84.6K | |
| Income Quality | 0.74 | 0.7 | 0.62 | 0.88 | 0.97 | 0.51 | |
| Roe | (1.2) | (2.72) | (5.54) | (3.89) | (1.71) | (1.8) | |
| Ev To Operating Cash Flow | (2.68) | (2.2) | (3.71) | (0.18) | 0.0262 | 0.0275 | |
| Pe Ratio | (2.76) | (1.95) | (2.58) | (0.46) | (0.38) | (0.4) | |
| Return On Tangible Assets | (1.12) | (1.98) | (2.87) | (2.53) | (1.48) | (1.55) | |
| Ev To Free Cash Flow | (8.2) | (2.68) | (2.2) | (3.69) | (0.18) | (0.17) | |
| Earnings Yield | (0.36) | (0.51) | (0.39) | (2.18) | (2.64) | (2.51) | |
| Intangibles To Total Assets | 8.03E-4 | 0.001021 | 0.0949 | 0.12 | 8.26E-4 | 7.85E-4 | |
| Net Debt To E B I T D A | 0.55 | 0.83 | 0.4 | 0.3 | 0.28 | 0.42 | |
| Current Ratio | 14.24 | 3.41 | 2.37 | 2.67 | 4.9 | 4.46 | |
| Tangible Book Value Per Share | 18.1 | 7.98 | 3.76 | 2.42 | 2.86 | 4.81 | |
| Graham Number | 94.27 | 62.6 | 52.66 | 28.82 | 17.81 | 16.92 | |
| Shareholders Equity Per Share | 18.12 | 8.0 | 4.72 | 3.08 | 2.87 | 4.97 | |
| Graham Net Net | 18.97 | 15.83 | 5.81 | 2.82 | 1.45 | 1.53 | |
| Enterprise Value Over E B I T D A | (2.08) | (1.54) | (2.28) | (0.15) | 0.0255 | 0.0268 | |
| Price Earnings Ratio | (2.76) | (1.95) | (2.58) | (0.46) | (0.38) | (0.4) | |
| Price Book Value Ratio | 3.33 | 5.32 | 14.31 | 1.78 | 0.65 | 0.68 | |
| Price Earnings To Growth Ratio | 0.043 | 42.53 | (0.13) | 0.008483 | 0.006929 | 0.006583 | |
| Days Of Payables Outstanding | 122.9K | 419.8K | 1.9K | 1.7K | 82.4K | 84.6K | |
| Price To Operating Cash Flows Ratio | (3.75) | (2.78) | (4.2) | (0.52) | (0.39) | (0.41) | |
| Price To Free Cash Flows Ratio | (3.75) | (2.78) | (4.18) | (0.52) | (0.47) | (0.49) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.94) | Return On Assets (1.04) | Return On Equity (3.21) |
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.